Skip to main content


Log in

Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease

  • CE - Research Letter to the Editor
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1


  1. Ferretti G, Bacchetti T, Johnston TP et al (2018) Lipoprotein(a): a missing culprit in the management of athero-thrombosis? J Cell Physiol 233:2966–2981.

    Article  CAS  PubMed  Google Scholar 

  2. Gragnano F, Calabrò P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228.

    Article  CAS  PubMed  Google Scholar 

  3. Fogacci F, Cicero AF, D’Addato S, D’Agostini L, Rosticci M, Giovannini M, Bertagnin E, Borghi C, Brisighella Heart Study Group (2017) Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med 37:49–55.

    Article  CAS  PubMed  Google Scholar 

  4. Scanu AM (1992) Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA, J Am Med Assoc 267:3326–3329.

    Article  CAS  Google Scholar 

  5. Rallidis LS, Pavlakis G, Foscolou A et al (2018) High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 269:29–34.

    Article  CAS  PubMed  Google Scholar 

  6. Marcucci R, Brunelli T, Fedi S et al (2005) Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. Eur J Clin Invest 35:1–7.

    Article  CAS  PubMed  Google Scholar 

  7. Schwartz GG, Ballantyne CM, Barter PJ et al (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol 3:164–168.

    Article  PubMed  Google Scholar 

  8. Milionis HJ, Filippatos TD, Loukas T et al (2006) Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187:170–176.

    Article  CAS  PubMed  Google Scholar 

  9. Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711.

    Article  CAS  Google Scholar 

  10. Chiarugi L, Prisco D, Antonucci E et al (2001) Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 154:129–135

    Article  CAS  PubMed  Google Scholar 

  11. Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058l.

    Article  Google Scholar 

  12. Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8:e010932.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gragnano F, Natale F, Concilio C et al (2018) Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. J Cardiovasc Med 19:75–77.

    Article  Google Scholar 

  14. Schettler VJJ, Neumann CL, Peter C et al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)—almost 5 years on. Atheroscler Suppl 30:50–55.

    Article  CAS  PubMed  Google Scholar 

  15. Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Paolo Calabrò.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

The study was carried out according to Declaration of Helsinki.

Informed consent

Patients gave their informed consent to participate to the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gragnano, F., Fimiani, F., Di Maio, M. et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med 14, 621–625 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: